<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments for Travel Conqueror</title>
	<atom:link href="http://www.travelconqueror.com/comments/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.travelconqueror.com</link>
	<description>Travel Conqueror - Travel Blog</description>
	<pubDate>Sun, 27 Jul 2008 08:33:39 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.5.1</generator>
		<item>
		<title>Comment on American Airlines Offering Tastier On Board Fare by EvalmSawLaw</title>
		<link>http://www.travelconqueror.com/american-airlines-offering-tastier-on-board-fare/#comment-228</link>
		<dc:creator>EvalmSawLaw</dc:creator>
		<pubDate>Thu, 17 Jul 2008 23:45:44 +0000</pubDate>
		<guid isPermaLink="false">http://www.travelconqueror.com/?p=5#comment-228</guid>
		<description>low-down Provides yet advice on AVANDIA as a timely and remarkable Treatment privilee for befitting strain 2 Diabetes Patients 
 
PHILADELPHIA, July 14, 2008 /PRNewswire-FirstCall/ -- GlaxoSmithKline announces today that the U.S. sustenance abd remedy charge (FDA) updated the prescribing low-down for AVANDIA(R) (rosiglitazone maleate) to subsume clinical findings from A Diabetes development advancement stab (accept), a 4- to- 6 year go-to-chaiorman examination of AVANDIA versus metformin and glyburide monoremedial lay out in recently diagnosed discernmentification 2 diabetes patients. The prooortion of patients with inaverage glucose direction at five years was 34 percent with glyburide, 21 percent with metformin and at omst 15 percent with AVANDIA. The alteration between AVANDIA and the comparators was tsatistically significant.</description>
		<content:encoded><![CDATA[<p>low-down Provides yet advice on AVANDIA as a timely and remarkable Treatment privilee for befitting strain 2 Diabetes Patients </p>
<p>PHILADELPHIA, July 14, 2008 /PRNewswire-FirstCall/ &#8212; GlaxoSmithKline announces today that the U.S. sustenance abd remedy charge (FDA) updated the prescribing low-down for AVANDIA(R) (rosiglitazone maleate) to subsume clinical findings from A Diabetes development advancement stab (accept), a 4- to- 6 year go-to-chaiorman examination of AVANDIA versus metformin and glyburide monoremedial lay out in recently diagnosed discernmentification 2 diabetes patients. The prooortion of patients with inaverage glucose direction at five years was 34 percent with glyburide, 21 percent with metformin and at omst 15 percent with AVANDIA. The alteration between AVANDIA and the comparators was tsatistically significant.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
